Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments
Clinical & Experimental Allergy, 04/27/2012Cameron EJ et al.
New macrolides have been developed which do not possess any antimicrobial activity and hence lack the ability to produce microbial resistance, but which still retain immunomodulatory effects. Potentially novel macrolides may overcome a significant barrier to the use of this type of drug for the long–term treatment of chronic inflammatory airway diseases.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.